Why Intra-Cellular Therapies Trounced the S&P 500 Today
Even on an earnings season day when a clutch of companies notched earnings beats, Intra-Cellular Therapies' (NASDAQ: ITCI) first-quarter beat was notably impressive. Investors liked what they saw in the company's freshly published earnings report, and they traded the stock up by nearly 24%. That absolutely crushed the 0.3% gain of the bellwether S&P 500 index on the day.
For the quarter, Intra-Cellular booked $35 million in revenue, almost double the $15.9 million the company earned in the same quarter last year. Nearly all ($34.8 million) of the former tally derived from the net product revenue of Caplyta, the company's bipolar depression treatment.
Image source: Getty Images.
Source Fool.com
